Cancer vaccine characterization: From bench to clinic

de la Luz-Hernandez, K; Rabasa, Y; Montesinos, R; Fuentes, D; Santo-Tomas, JF; Morales, O; Aguilar, Y; Pacheco B.; Castillo A.

Keywords: mass spectrometry, monoclonal antibody, Comparability studies, Cancer vaccine


Background: The development of safe, effective, and affordable vaccines has become a global effort due to its vast impact on overall world health conditions. A brief overview of vaccine characterization techniques, especially in the area of high-resolution mass spectrometry, is presented. It is highly conceivable that the proper use of advanced technologies such as high-resolution mass spectrometry, along with the appropriate chemical and physical property evaluations, will yield tremendous in-depth scientific understanding for the characterization of vaccines in various stages of vaccine development. This work presents the physicochemical and biological characterization of cancer vaccine Racotumomab/alumina, a murine anti-idiotypic antibody that mimics N-glycolyl-GM3 gangliosides. This antibody has been tested as an anti-idiotypic cancer vaccine, adjuvated in Al(OH)(3), in several clinical trials for melanoma, breast, and lung cancer. Methods: Racotumomab was obtained from ascites fluid, transferred to fermentation in stirred tank at 10 L and followed to a scale up to 41 L. The mass spectrometry was used for the determination of intact molecule, light and heavy chains masses; amino acids sequence analysis, N- and C-terminal, glycosylation and posttranslational modifications. Also we used the DLS for the size distribution and zeta potential analysis. The biological analyses were performed in mice and chickens. Results: We observed differences in glycosylation pattern, charge heterogeneity and structural stability between in vivo-produced and bioreactor-obtained Racotumomab products. Interestingly, these modifications had no significant impact on the immune responses elicited in two different animal models. Conclusions: We are demonstrated that this approach could potentially be more efficient and effective for supporting vaccine research and development. (C) 2014 Published by Elsevier Ltd.

Más información

Título según WOS: Cancer vaccine characterization: From bench to clinic
Título de la Revista: VACCINE
Volumen: 32
Número: 24
Fecha de publicación: 2014
Página de inicio: 2851
Página final: 2858
Idioma: English


Notas: ISI